Evidence map›Paper›PMID 41574715›Full record

ArticleTechnology in cancer research & treatment

Immunotherapy Response Predictive Score Based on Tumor Microenvironment Profiles for Predicting Immunotherapy Outcomes in Advanced Head and Neck Cancer.

Hui-Ching Wang, Mei-Ren Pan, Leong-Perng Chan, Chun-Chieh Wu, Yu-Hsuan Hung, Jeng-Shiun Du, Shih-Feng Cho, Meng-Chun Chou, Hui-Ting Tsai, Che-Wei Wu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hui-Ching WangGraduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.ORCID 0000-0002-8232-0387
Mei-Ren PanGraduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Leong-Perng ChanFaculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Chun-Chieh WuDepartment of Pathology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Yu-Hsuan HungCenter for Cancer Research, Kaohsiung Medical University, Kaohsiung, Taiwan.
Jeng-Shiun DuGraduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Shih-Feng ChoDepartment of Internal Medicine, Division of Hematology and Oncology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Meng-Chun ChouDepartment of Nursing, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Hui-Ting TsaiDepartment of Nursing, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Che-Wei WuFaculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Yi-Chang LiuDepartment of Internal Medicine, Division of Hematology and Oncology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Li-Tzong ChenDepartment of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Sin-Hua MoiGraduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.ORCID 0000-0002-4082-1909

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ObjectivesThis retrospective study presents an integrative transcriptomic approach for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) by developing an immune response predictive score (IORPS) derived from tumor microenvironment (TME) transcriptomic profiles.MethodsA total of 30 R/M HNSCC patients treated with pembrolizumab or nivolumab, with available immune TME profiling data, were analyzed. IORPS was constructed based on the cumulative weighting of differentially expressed gene (DEG) expression levels. The predictive performance of conventional biomarkers, individual DEGs, and IORPS was evaluated for immunotherapy response and prognostic outcomes. The clinical relevance of IORPS was further validated using two external cohorts from the GEO database (CLB-IHN: GSE159067 and GHPS: GSE159141).ResultsBy comparing immune tumor microenvironment (TME) profiles between good and poor responders,

Indexed as

Biomarkers, TumorHead and Neck NeoplasmsImmunotherapyTumor MicroenvironmentFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisTranscriptomeTreatment OutcomeBiomarkers, Tumorhead and neck squamous cell carcinomaimmunotherapyprincipal component analysistranscriptome profilingtumor microenvironment (TME)

Identifiers

PMID41574715
PMCPMC12833181

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.